-
Mar 26, 2025 | 
parkinsonsnewstoday.com | Andrea Lobo |Diana Delgado |Lindsey Shapiro |Margarida Maia
Newronika is preparing for the commercial launch of AlphaDBS — a next-generation adaptive deep brain stimulation (DBS) system for treating Parkinson’s disease — at selected markets in Europe this year, following CE Mark approval in the European Union.
-
Feb 28, 2025 | 
parkinsonsnewstoday.com | Marisa Wexler |Mollie Lombardi |Lindsey Shapiro |Diana Delgado
Treatment with psilocybin — the hallucinogenic agent in magic mushrooms — may help to prevent damage to the brain following mild head injuries, according to a new study done in rats. Head injuries are an established risk factor for Parkinson’s disease, as well as Alzheimer’s and other forms of dementia. The study, “Psilocybin as a Treatment for Repetitive Mild Head Injury: Evidence from Neuroradiology and Molecular Biology,” was published online as a preprint.
-
Jan 13, 2025 | 
cysticfibrosisnewstoday.com | Andrea Lobo |Margarida Maia |Marisa Wexler |Diana Delgado
A Phase 1b trial assessing the safety of RCT2100, Recode Therapeutics’ inhaled therapy candidate for people with cystic fibrosis (CF), has now dosed its first patient in the U.S. The trial already was underway in Europe. RCT2100 is being developed for patients who do not respond to or are not eligible for CFTR modulator therapies — individuals who, according to the company, account for about 10% of the CF community.
-
Mar 25, 2024 | 
ancavasculitisnews.com | Margarida Maia |Diana Delgado |Steve Bryson |Marta Costa Figueiredo
ANCA-associated vasculitis (AAV) patients receiving a cumulative dose of at least 935 mg of glucocorticoids over six months are more likely to see clinically meaningful side effects, according to a study using calculations based on the Glucocorticoid Toxicity Index (GTI). The findings suggest the GTI, which considers the frequency and severity of glucocorticoid-related side effects, may help identify who’s at a higher risk for side effects in research and clinical settings.
-
Feb 19, 2024 | 
parkinsonsnewstoday.com | Mary M. Chapman |Marisa Wexler |Mary Beth Skylis |Diana Delgado
Parkinson’s disease patients who experience tremor are invited to complete an online survey aimed at assessing the difficulties due to this common disease symptom, with an ultimate goal of promoting more effective treatments.
-
Feb 9, 2024 | 
parkinsonsnewstoday.com | Andrea Lobo |Sherri Woodbridge |Diana Delgado |Margarida Maia
Long-term practice of the Chinese martial art tai chi for Parkinson’s disease was shown to ease nonmotor symptoms among patients in a yearlong trial in China. Specifically, improved cognition was seen among people with the neurodegenerative disease after one year of the exercise program, according to study data. Conversely, at the six-month mark, taking part in the traditional Chinese martial art helped lessened daytime sleepiness in these patients as compared with those in the control group.
-
Dec 11, 2023 | 
fapnewstoday.com | Marisa Wexler |Lindsey Shapiro |Diana Delgado |Forest Ray
Screening for toxic protein clumps using biopsies and advanced imaging techniques may help people carrying mutations that cause hereditary transthyretin amyloidosis (ATTRv) — a group of conditions that includes familial amyloid polyneuropathy (FAP) — to get an early start on disease-modifying treatment (DMT). That’s according to a study in France that looked back at data from ATTRv carriers — those with a disease-causing mutation — who had normal results on standard nerve function tests.
-
Aug 5, 2023 | 
semana.com | Diana Delgado
Privacy Preference CenterWhen you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies.
-
May 31, 2023 | 
cushingsdiseasenews.com | Andrea Lobo |Diana Delgado |Marisa Wexler |Patricia Valerio
A type of minimally invasive surgery to remove pituitary tumors through the nose, called endoscopic transsphenoidal surgery, was found to be safe and led to remission from Cushing’s disease, with patients seeing no recurrences, a study in China reports. The procedure involved identifying pituitary and tumor layers before the tumor’s removal, instead of suctioning or scraping tumor tissue. This contributed to improving the removal of the total tumor and preserving normal pituitary function.
